Overview of Colistimethate

Property	Description
Active ingredient	Colistimethate Sodium (prodrug of Colistin)
Form	Lyophilized powder for solution
Pharmacological class	Polypeptide antibiotic (Polymyxin class)
Common use	Against multi-drug resistant (MDR) Gram-negative bacteria
Origin	Semi-synthetic derivative

Colistimethate is a highly specialized antibiotic belonging to the Polymyxin class of polypeptide antibiotics, a group of compounds whose clinical relevance has been recognized globally. It is reserved for treating severe, persistent infections caused by certain Gram-negative bacteria. It is considered a crucial, re-emerged medicine used primarily when many common drug treatments have proven ineffective against highly multi-drug resistant (MDR) pathogens.

What Type of Antibiotic is Colistimethate Sodium?

Colistimethate Sodium is a semi-synthetic substance that functions as an inactive prodrug of the powerful antibiotic Colistin. This prodrug status is a key differentiating feature of this INN, as the body's gradual conversion process is intended to influence drug delivery and tolerability. The administered Colistimethate is chemically modified, meaning it has minimal activity until it is transformed into the active Colistin within the patient's body. This conversion is central to its therapeutic action, where the active Colistin component exerts a rapid bactericidal effect.

Colistimethate Form and Purpose

Colistimethate is typically supplied as a lyophilized powder for solution, which is a highly stable, dried form that requires reconstitution with a sterile vehicle, such as water or saline, immediately prior to administration. This preparation allows the drug to be administered both systemically through intravenous injection or infusion, and via inhalation for treating localized pulmonary infections. The drug's dual route capability (IV and inhalation) is a significant positioning factor that enables its targeted use. Its potent mechanism of cell membrane disruption makes Colistimethate a powerful option, and it is classified as a "last-resort" agent to conserve its effectiveness against the most difficult-to-treat resistant strains.

Regulatory References

global health organizations (NIH)

What side effects are possible with Colistimethate?

Possible Side Effects and Safety Information

The officially documented safety profile for Colistimethate Sodium emphasizes its potential for toxicity within specific organ systems, a characteristic shared with its pharmacological class. The primary safety concerns detailed in regulatory documents are Nephrotoxicity (effects on the kidneys) and Neurotoxicity (effects on the nervous system).

Adverse Reaction Classifications

Regulatory agencies classify adverse effects by frequency and system. The most significant finding is that Nephrotoxicity is officially classified as a very common adverse reaction, meaning it is frequently anticipated. Manifestations of Neurotoxicity, such as Paresthesia (tingling or numbness in the face or extremities) and vertigo, are generally classified as common reactions.

System-Organ Class	Key Adverse Reaction (Label-Documented)
Renal and urinary disorders	Nephrotoxicity, Acute Renal Failure
Nervous system disorders	Paresthesia, Vertigo, Neuromuscular blockade
Respiratory disorders	Bronchospasm (primarily with inhalation)

Safety Constraints and Serious Reactions

The risk of developing the principal toxicities (kidney and nerve damage) is explicitly stated in regulatory information to be dose-dependent and linked to total cumulative exposure during the treatment period. This establishes a time- and exposure-related pattern for safety concerns.

Two serious adverse reactions specifically documented include Acute Renal Failure and Respiratory Arrest, the latter being a rare but critical event linked to potential profound neuromuscular blockade.

Official safety constraints note that patients with pre-existing renal impairment are at an increased risk for both nephrotoxicity and neurotoxicity. Furthermore, a known contraindication is the presence of severe Myasthenia Gravis due to the risk of exacerbating muscle weakness.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Colistimethate is documented in regulatory labeling to primarily affect the renal and neuromuscular systems, resulting in potentially severe manifestations. The documented clinical signs of overdose include neurotoxicity symptoms such as dizziness, ataxia, speech disturbances (slurred speech), perioral paraesthesia, and paraesthesia in the extremities. A critical outcome of overdosage is neuromuscular blockade, which leads to generalized muscular weakness and, most seriously, apnea (cessation of breathing) and possible respiratory arrest.

Acute renal damage, or acute renal failure, is also a documented consequence, characterized by signs like oliguria (decreased urine output) and the laboratory findings of elevated serum BUN and creatinine. The official prescribing information mandates that patients must seek immediate medical attention for all suspected overdosage scenarios and contact a Poison Control Centre immediately.

Official management strategies are limited to supportive measures because no specific antidote is known for Colistimethate. Treatment includes providing symptomatic and supportive care, applying the usual medical regimen for managing oliguria or anuria, and considering dialysis specifically in cases of massive overdosage. Regulatory documents also note that the possibility of apnea and neuromuscular blockade is increased in patients with pre-existing impaired renal function. Furthermore, subjective neurotoxic symptoms may not manifest reliably in infants or young children.

Therapeutic Uses of Colistimethate

What Colistimethate Treats: Main Uses and Benefits

Colistimethate is commonly used in clinical settings that involve acute or unstable symptom patterns associated with conditions presenting with systemic or localized discomfort caused by Gram-negative bacteria that have become resistant to most other available antibiotics. It is utilized to help with infections due to sensitive strains of certain Gram-negative bacilli, including Pseudomonas aeruginosa and Klebsiella pneumoniae. The primary therapeutic benefit is applied across domains where additional symptomatic support is needed, and contributes to easing the overall symptom load.

It is relevant in contexts involving heightened systemic burden due to hospital-acquired infections, such as bacteremia (bloodstream infection), clinical sepsis, and ventilator-associated pneumonia. This medication contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability during the acute bacterial episode. It is also considered relevant in patients with chronic respiratory conditions, such as cystic fibrosis, for managing symptoms associated with persistent pulmonary colonization by resistant bacteria.

Quick Fact: Supports management of Symptoms Related to Systemic Functional Stress

Eligibility and Restrictions for Use

Official Eligibility and Population Restrictions

Colistimethate use is restricted by specific patient history and clinical conditions as mandated by regulatory documents.

Category	Description
Populations Contraindicated	Patients with a history of hypersensitivity to Colistimethate Sodium, its active component Colistin, or any other Polymyxin-class antibiotic. Patients with Myasthenia Gravis are also contraindicated in some jurisdictions.
Age-Related Eligibility	Adults and Pediatric Patients are generally eligible for systemic use. Infants under 1 year of age require caution due to immature renal function. The safety and efficacy of inhaled formulations have not been established for children under six years of age.
Condition-Specific Rules	Impaired Renal Function requires the greatest caution and mandatory dosage reduction for systemic use to prevent drug accumulation. Patients with Porphyria and Myasthenia Gravis must be treated with extreme caution.
Pregnancy/Lactation Status	Pregnancy use is generally not recommended as the drug crosses the placenta. Breastfeeding is not recommended due to the secretion of the drug into human milk.

The official eligibility profile is defined by these contraindications and conditional restrictions, determining who can receive the medicine under strict regulatory guidelines.

What should I know about interactions with other medicines?

Interaction Scope: Official Regulatory Information

Colistimethate interacts with other medicines primarily through two types of additive risk as documented in official government labeling. These interactions structure the constraints on co-administration.

Classification	Interacting Agents (Examples)	Interaction-Related Restriction
Additive Nephrotoxicity	Sodium cephalothin, Potentially nephrotoxic drugs (broad class)	Concomitant use with sodium cephalothin should be avoided due to enhanced nephrotoxicity; use of all potentially nephrotoxic drugs requires great caution.
Potentiation of Neuromuscular Blockade	Curariform muscle relaxants (e.g., tubocurarine, succinylcholine), Certain other antibiotics (e.g., Aminoglycosides, Polymyxin B)	Potentiate the neuromuscular blocking effect and must be used with extreme caution.

Official regulatory documents note that the risk of both apnea and neuromuscular blockade is increased in patients with impaired renal function. This is due to the drug's slower clearance, which may lead to higher serum levels. No interactions with food, alcohol, or herbal products are explicitly documented in regulatory sources. The combination restrictions are defined by the severity of the potential adverse pharmacodynamic effects.

Mechanism of Action

Colistimethate sodium (CMS) is a pro-drug that undergoes hydrolysis in the body to form the active antimicrobial agent, colistin (polymyxin E). Colistin is a polycationic polypeptide that initiates its effect by interacting electrostatically with the negatively charged phosphate groups of the lipopolysaccharide (LPS) component in the outer membrane of Gram-negative bacteria. This binding displaces divalent cations, specifically Ca^2+ and Mg^2+, which normally stabilize the outer membrane structure. The resulting destabilization alters the integrity of the bacterial outer membrane, increasing its permeability. Colistin then inserts its hydrophobic acyl chain into the cell's inner membrane phospholipid bilayer. This insertion further compromises the structural integrity of both the outer and inner membranes, resulting in the efflux of essential cytoplasmic components and subsequent cell lysis at the cellular level.

Dosage and Administration Information

How to Use Colistimethate: Official Administration Guidelines

Colistimethate is administered through specialized procedures that must strictly adhere to established clinical protocols to ensure appropriate dosing and delivery. The drug is typically supplied as a lyophilized powder that requires reconstitution with a sterile diluent, which is achieved by gently swirling the vial to prevent frothing.

Administration Routes and Schedules

Systemic treatment is administered via intravenous (IV) infusion or intramuscular (IM) injection, while localized treatment for pulmonary infections is administered via inhalation (nebulization). Dosing for systemic use is complex and typically involves multiple divided doses throughout the day.

Administration Route	Frequency Pattern	Standard Dosing Unit	Procedural Timing
Intravenous (IV)	Divided daily use (2-4 times/day)	International Units (IU) or mg of Colistin Base Activity (CBA)	Infused over 3 to 5 minutes (intermittent)
Inhalation	Divided daily use (2-3 times/day)	International Units (IU)	Specific nebulization equipment required

Dosing and Special Conditions

Standard adult maintenance doses range from 2.5 to 5.0 mg/kg/day CBA, but an initial loading dose may be required in critically ill patients to achieve adequate concentration faster. A key procedural requirement is the mandatory adjustment of the dose for individuals with impaired renal function (kidney issues), where the daily dose and frequency must be reduced based on calculated creatinine clearance. For obese patients, the dose must be calculated using ideal body weight. Treatment duration is determined by the specific condition being addressed, ranging from short courses for acute systemic infections to long-term cyclic use for chronic pulmonary conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colistimethate

Evidence for Use in Infections Due to Multidrug-Resistant (MDR) Gram-Negative Bacteria

Colistimethate was studied for use in people facing severe infections, often in hospital settings, caused by bacteria that are challenging because they show resistance to many other antibiotic treatments, such as Acinetobacter baumannii. Researchers used various methods, including Randomized Controlled Trials (RCTs) and observational cohort studies, to examine this use. The main outcomes measured included microbiological clearance and overall survival over a short period. The data show variability in survival rates and reflected the high severity of illness in the study populations.

Evidence for Use in Ventilator-Associated and Hospital-Acquired Pneumonia

Research examined the use of Colistimethate in adult patients who developed serious lung infections while in the hospital, specifically Ventilator-Associated Pneumonia (VAP) and Hospital-Acquired Pneumonia (HAP). Studies evaluated measurements related to changes in respiratory symptoms and whether the resistant bacteria were cleared from the lungs. Research describes the frequency of specific clinical measurements that were monitored during the study period. A key area where certainty remains low is identifying the most effective way to administer the drug (intravenously versus directly inhaled into the lungs), as different studies employed different approaches.

Evidence for Use in Combination Therapy Protocols

Colistimethate was observed in trials that examined its use in combination with a second antibiotic compared to its use alone. These studies aimed to find patterns related to adding another drug. The studies reported measurements of clinical success and bacterial eradication, but findings were mixed regarding whether the combination provided a consistent pattern across all measured outcomes. Studies monitored both groups for high-level outcomes measured during the study period. Comparative evidence is lacking for many potential antibiotic combinations, making it difficult to draw broad conclusions.

What is Still Uncertain About Colistimethate Research

This body of research highlights what is known — and what is still uncertain. The main limitations include the fact that evidence quality varies across studies, with many findings coming from reviews rather than high-certainty RCTs. Long-term effects are not fully established because research generally does not track patients for several months or longer. Inconsistent Findings also lead to mixed findings on specific measured outcomes. Data for special populations (like children or pregnant individuals) are still emerging, and it is difficult to generalize results broadly.

Frequently Asked Questions (FAQ)

Common questions about Colistimethate (FAQ)

Q: Why might the inhaled form of Colistimethate lead to coughing or wheezing?

Official product information states that the inhaled form of Colistimethate can cause side effects like coughing or bronchospasm (tightening of the airways). These respiratory symptoms may lessen over time as treatment continues. Regulatory guidance suggests that a beta-2-agonist (a type of bronchodilator) may be administered before each dose to help manage this common reaction.

Q: Is it safe to use Colistimethate concurrently with other antibiotics given by injection (IV)?

According to regulatory documents, the concurrent use of Colistimethate with other medicines is restricted, especially if they carry a known risk of nephrotoxicity (kidney damage) or neurotoxicity (nerve damage). Specific injectable antibiotics, such as those in the aminoglycoside class (e.g., Gentamicin), are listed as medicines for which caution should be exercised, and concurrent use should sometimes be avoided due to the increased risk of adverse effects.

Q: What is the meaning of the term 'nephrotoxicity' in plain language?

Nephrotoxicity is the term used to describe a toxic or harmful effect on the kidneys. Official documents explain that this is a common, anticipated side effect of Colistimethate, which is why kidney function is closely monitored during treatment. Regulatory information indicates that potential manifestations of this effect include a decrease in the amount of urine produced or changes in routine blood tests, such as increased creatinine levels.

Q: Is there a known difference in the risk of side effects between the intravenous (IV) and inhaled administration routes?

Yes, the risk profiles differ based on the administration route. Because the inhaled form provides minimal systemic absorption (entry into the bloodstream), the risk of systemic toxicities like kidney or nerve damage is considered lower than with intravenous (IV) injection. However, local side effects, such as coughing and bronchospasm, are more commonly reported with the inhaled method.

Q: Is kidney toxicity from Colistimethate treatment usually temporary?

According to official prescribing information, kidney toxicity, known as nephrotoxicity, is generally considered reversible once the drug is stopped. However, even after treatment ends, changes in laboratory values used to track kidney function may continue for a period of one to two weeks before stabilizing.

Q: What signs might indicate a patient is experiencing kidney-related issues while taking the drug?

Potential signs of kidney-related issues (nephrotoxicity) include observable changes such as a diminishing urine output. This effect is typically detected by laboratory tests that show an increase in values like Blood Urea Nitrogen (BUN) and serum creatinine. Official guidelines indicate that the drug's discontinuation may be required if these signs are observed.

Q: What can be done to manage the throat irritation or unpleasant taste from inhaled Colistimethate?

The inhaled powder formulation is commonly associated with local effects, including an unpleasant taste and/or throat irritation. Product instructions recommend a procedure where the mouth is rinsed with water and the rinse is then spit out after each dose to help clear any remaining drug powder.

Q: Does being an older patient increase the risk of side effects from this antibiotic?

Official guidance notes that dose selection may require caution for older patients, as they may more frequently have some level of reduced kidney, liver, or heart function. Regulatory documents also note that increasing age (particularly over 65) may be associated with an increased rate of neurological adverse events due to reduced organ clearance.

Q: Are there any special instructions for avoiding tasks that require focus, like driving, during treatment?

Yes, official safety information states that engaging in activities like driving vehicles or operating hazardous machinery is not recommended while receiving this treatment. This restriction is in place because the medicine can cause transient neurological effects, including feelings of dizziness, vertigo (a sensation of spinning), and potentially blurred vision.

Q: What does 'Therapeutic Drug Monitoring' involve for patients on Colistimethate?

Therapeutic Drug Monitoring (TDM) is a clinical practice where healthcare providers measure the concentration of the drug in a patient's blood. This monitoring is used to assist in maintaining drug levels within an appropriate range and help mitigate the risk of accumulation and toxicity, particularly for patients with impaired kidney function.

Q: Can Colistimethate cause temporary changes in voice or a sore throat?

Yes, the inhaled form of the drug is associated with local side effects in the mouth and throat. These commonly reported effects include throat irritation and dysphonia (difficulty or change in speaking/voice).

Q: Does Colistimethate have any known effect on fertility in humans?

Official non-clinical data from animal studies indicates that the active component of the drug, colistin, did not affect male or female fertility. However, the drug's effect on human fertility has not been fully established through extensive clinical research.

Q: Is it true that Colistimethate is a mixture of chemical components rather than a single pure substance?

Yes. The active antibiotic component, known as Colistin (which Colistimethate converts into), is not a single pure substance. Instead, regulatory documents describe it as a mixture of closely related chemical components, primarily Polymyxins E1 and E2. This is common for antibiotics derived from natural sources.

Q: What is the difference between the brand name Colobreathe and the generic name Colistimethate?

Colistimethate (or Colistimethate Sodium) is the official generic name for the active chemical ingredient. Colobreathe is a specific brand name given to the dry powder formulation of this medicine that is used for inhalation.

Q: Are there any known interactions between Colistimethate and common pain relievers?

Regulatory data indicates potential interactions with some common pain relievers, specifically Acetaminophen and Acetylsalicylic acid (Aspirin). These interactions may influence how efficiently the body clears the drug, which could potentially result in higher levels of the antibiotic in the system.

Q: Why is it important to use a bronchodilator medicine before using inhaled Colistimethate?

Official product information suggests that a bronchodilator medicine may be administered before inhaled Colistimethate. This procedural step helps to control or relieve bronchospasm (tightening of the airways) and coughing, which are frequently reported side effects of the inhaled medicine itself.

How should Colistimethate be stored and disposed of?

Storage Requirements for Colistimethate

The unreconstituted powder must be stored at Controlled Room Temperature, specifically between 20 to 25C (68 to 77F), with a permitted range of 15 to 30C. Vials must be kept in the outer carton to ensure protection from light.

Once the powder is reconstituted, the solution should not be frozen. The product’s stability depends on the concentration and temperature:

Up to 7 Days: The primary reconstituted solution is stable for up to 7 days when stored at either refrigerated temperatures (2 to 8C) or at controlled room temperature.
Immediate Use: Solutions that have been further diluted or prepared in lower concentrations must be used immediately.

Disposal and Child Safety

Colistimethate must be stored out of the sight and reach of children. The prepared solution is for single use only, and any portion remaining after administration must be discarded. Unused or expired product and related waste material must be disposed of in accordance with local regulatory requirements and should not be thrown into household waste or wastewater.

Colistimethate